FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: opalapril who wrote ()	9/28/1999 9:51:00 AM
From: opalapril	Read Replies (1) of 75

It seems only fitting to begin this thread with a brief discussion of today's press release from Xoma. This ill-starred company has been hanging on with whitened fingernails since the early 1980's. E-5 was a spectacular failure, driving the company's stock price from the mid-$30s to $1. In late September, lightning struck twice when the P-3 trial of Neuprex for trauma victims was halted for lack of efficacy and the stock tanked by 55% to around $2 a share. So, what does Xoma do? Today they issue a press release touting rBPI for chlamydia. It is, we are assured, "effective in vitro." Xoma also promises in the future to "be presenting and publishing more clinically-related research as well." Anyone care to invest in a biotech whose only successful product to date has been snazzy research papers and convincing press releases?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext